Search

SOUTH PLAINFIELD, N.J., June 30, 2014 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the initiation of a global confirmatory Phase 3 clinical trial of Translarna(TM) (ataluren), an investigational [...]

- Data Demonstrate Positive Trends in Lung Function and Pulmonary Exacerbations - SOUTH PLAINFIELD, N.J., May 16, 2014 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the results [...]

-Mean absolute treatment difference in lung function across all patients was 2.1 percentage points (p=0.20) and mean relative treatment difference was 5.0% (p=0.06)(n=69); study did not meet its primary endpoint- [...]

- Interim analysis showed 46% of patients experienced at least 5% absolute improvement in lung function (FEV 1 ) from baseline; 30% of patients experienced at least 10% absolute improvement [...]

- Study shows that treating CF by targeting the underlying cause of the disease leads to significant clinical benefits among people with the G551D mutation - CAMBRIDGE, Mass. -- Vertex [...]

SOUTH PLAINFIELD, N.J., July 1, 2011 /PRNewswire/ -- PTC Therapeutics, Inc. (PTC) today announced the publication of data from a Phase 2 study of ataluren, an investigational new drug, in [...]

- Data Presented at 34th European Cystic Fibrosis Conference - MONMOUTH JUNCTION, N.J., June 10, 2011 /PRNewswire/ -- Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, today announced positive data [...]

-13.17 mmol/L reduction in sweat chloride in one arm supports further evaluation of a combination approach to treating the root cause of cystic fibrosis- CAMBRIDGE, Mass. -- Vertex Pharmaceuticals Incorporated [...]

- Trial completion is expected in 2011 - SOUTH PLAINFIELD, N.J., Dec. 21, 2010 /PRNewswire/ -- PTC Therapeutics, Inc. announced today that it has completed enrollment of a Phase 3 [...]

-Treatment with VX-770 resulted in improvements in lung function and markers of disease- -There were no discontinuations of treatment due to adverse events- -Late-stage Phase 3 clinical trials for VX-770 [...]

- Data show that ataluren restores the production of functional CFTR protein - SOUTH PLAINFIELD, N.J., Nov. 15, 2010 /PRNewswire/ -- PTC Therapeutics, Inc. today announced the publication of data [...]

-Primary endpoints of safety, tolerability and effect on CFTR function as measured by sweat chloride- -Phase 2a proof of mechanism clinical trial to enroll people with the most common mutation [...]

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced an interim analysis of data from an ongoing Phase 2 study of VX-809 and KALYDECO™ (ivacaftor) that showed significant improvements in lung function (FEV1) [...]

Vertex Pharmaceuticals Inc. has announced the initiation of a Phase 2a clinical trial that will evaluate multiple combinations of VX-770 and VX-809, investigational oral cystic fibrosis transmembrane conductance regulator (CFTR) [...]

M2 PHARMA-October 15, 2010-Discovery Labs completes Phase IIa study of aerosolised KL4 surfactant in cystic fibrosis(C)2010 M2 COMMUNICATIONS 15 October 2010 - US Discovery Laboratories Inc (NASDAQ: DSCO) said today [...]

Genaera Corp. (GENR) announced the start of its pivotal phase II clinical trial for the mucoregulator drug, Lomucin, in people with cystic fibrosis (CF). Cystic Fibrosis Foundation Therapeutics, Inc., (CFFT) [...]

Genaera Corp. (GENR) announced the start of its pivotal phase II clinical trial for the mucoregulator drug, Lomucin, in people with cystic fibrosis (CF). Cystic Fibrosis Foundation Therapeutics, Inc., (CFFT) [...]

Genaera Corp. (GENR) announced the start of its pivotal phase II clinical trial for the mucoregulator drug, Lomucin, in people with cystic fibrosis (CF). Cystic Fibrosis Foundation Therapeutics, Inc., (CFFT) [...]

Altus Pharmaceuticals, Inc., announced that it has successfully completed a phase II clinical trial of TheraCLEC in cystic fibrosis (CF) patients with malabsorption due to pancreatic insufficiency. Altus' phase II [...]

Altus Pharmaceuticals, Inc., announced that it has successfully completed a phase II clinical trial of TheraCLEC in cystic fibrosis (CF) patients with malabsorption due to pancreatic insufficiency. Altus' phase II [...]

Targeted Genetics Corporation (TGEN) reported that its phase 2 clinical trial of tgAAVCF in patients with mild to moderate cystic fibrosis (CF) failed to meet its primary endpoint of statistically [...]

Targeted Genetics Corporation (TGEN) reported that its phase 2 clinical trial of tgAAVCF in patients with mild to moderate cystic fibrosis (CF) failed to meet its primary endpoint of statistically [...]